EDAP TMS S.A. - רווח החברה לפני מסים, ריבית ופחת EDAP

EDAP TMS S.A. generates stable profits from clinics' dependence on services and consumables for prostate therapy installations. EBITDA reflects the cash flow dynamics, where 0.00 shows the current volume of this metric. Success is based on insurance payouts and physician training, while the growth of Focal One system sales in the US serves as the key driver.

The business of EDAP TMS S.A. (EDAP) depends on the adoption rate of HIFU therapy and the stability of insurance reimbursements, making operational resilience critically important. By analyzing current EBITDA, an investor assesses the actual cash flow from core operations before depreciation and taxes, determining the company's ability to cover high physician training and equipment costs during a recession.